Loading provider…
- Featuresarrow_drop_down
- Solutionsarrow_drop_down
Loading provider…
Your Medical Sales Assistants that help you easily find, convert and close your ideal providers
Gynecologic Oncology Physician in Minneapolis, MN
NPI: 1265466809Primary Practice Location
M HEALTH FAIRVIEW SOUTHDALE HOSPITAL
6401 France Ave S, Edina, MN
Primary Employer
M Health Fairview Heart Clinic
fairview.org
HQ Phone
Get M.D. Melissa's Phone Numberphone_androidMobile
Get M.D. Melissa's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardMN State Medical License
MN State Medical License
2002 - 2025
WI State Medical License
2023 - 2025
American Board of Obstetrics and Gynecology
Obstetrics & Gynecology
American Board of Obstetrics and Gynecology
Gynecologic Oncology
University of Minnesota
Residency • Obstetrics and Gynecology
1998 - 2002
Chicago Medical School at Rosalind Franklin University of Medicine and Science
Medical School
Until 1998
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99214Established patient office or other outpatient visit, 30-39 minutes | 18 | 25 |
| 2 | 99213Established patient office or other outpatient visit, typically 15 minutes | 15 | 17 |
| 3 | 99215Established patient office or other outpatient, visit typically 40 minutes | 11 | 14 |
A model for patient-direct screening and referral for familial cancer risk
Authors: Kristin B. Niendorf, Melissa A. Geller, Rachel Isaksson Vogel, Timothy R. Church, Anna Leininger, Angela Bakke, Robert D. Madoff
Publication Date: 2016-10
A multi-institutional review of outcomes of endometrial stromal sarcoma
Authors: Peter Argenta, Kimberly Resnick, Warner Huh, Charles Leath
Journal: Gynecol Oncol
Publication Date: 2007-02-23
A multi-institutional study of outcomes in stage I-III uterine carcinosarcoma
Authors: Elizabeth L. Dickson, Rachel Isaksson Vogel, Paola A. Gehrig, S.R. Pierce, Laura J. Havrilesky, Angeles Alvarez Secord, Joseph A. Dottino, Amanda N. Fader, Stephanie Ricci, Melissa A. Geller
Publication Date: 2015-11
Lead Sponsor: Masonic Cancer Center, University of Minnesota
Collaborators: National Cancer Institute (NCI)
Intervention / Treatment: DRUG: Fludarabine, DRUG: CY, DRUG: FT536
Lead Sponsor: Masonic Cancer Center, University of Minnesota
Collaborators: National Cancer Institute (NCI)
Intervention / Treatment: DRUG: FT538, BIOLOGICAL: Enoblituzumab
Lead Sponsor: Masonic Cancer Center, University of Minnesota
Intervention / Treatment: DRUG: HCW9218
